Haddadin Yezan Munther
SEC insider (Form 3/4/5 filer). CIK 0001718004. Director at Outlook Therapeutics, Inc. (OTLK). 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 2, 2026. Located in ISELIN, NJ.
Companies Haddadin Yezan Munther has filed insider reports for
- Outlook Therapeutics, Inc. (OTLK): Director
Haddadin Yezan Munther
CIK: 0001718004
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Outlook Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 2, 2026OTLK
Outlook Therapeutics, Inc.
PurchaseDirect29K shares at avg. $0.83$24K - May 26, 2026OTLK
Outlook Therapeutics, Inc.
PurchaseDirect34K shares at avg. $0.44$15K - Oct 3, 2025OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
96K shares- - Oct 1, 2025OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
286.7K shares- - Oct 3, 2024OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
19.8K shares- - Oct 1, 2024OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
132.3K shares- - Oct 1, 2024OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
56.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 2, 2026 | OTLK Outlook Therapeutics, Inc. | Purchase | 29,000 | $0.83 | $24,145 | Direct |
| May 26, 2026 | OTLK Outlook Therapeutics, Inc. | Purchase | 34,000 | $0.44 | $14,960 | Direct |
| Oct 3, 2025 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 95,969 | - | - | Direct |
| Oct 1, 2025 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 286,734 | - | - | Direct |
| Oct 3, 2024 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 19,771 | - | - | Direct |
| Oct 1, 2024 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 132,293 | - | - | Direct |
| Oct 1, 2024 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 56,636 | - | - | Direct |
1-7 of 7 transactions